PDUFA dates April 2024: FDA calendar and catalysts.
2 PDUFA dates fell in April 2024: ANKTIVA (April 23), IBRX (April 23). The FDA calendar also recorded 53 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
PDUFA dates in April 2024
| PDUFA date | Company | Ticker | Drug | Indication | Source |
|---|---|---|---|---|---|
| April 23, 2024 | ImmunityBio, Inc. | IBRX | ANKTIVA (inbakicept) | sec_424b, filed 2025-07-28 | |
| April 23, 2024 | ImmunityBio, Inc. | IBRX | Not named | sec_424b, filed 2025-07-28 |
Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months
April 2024: other FDA decisions and filings
April 2024: dated readouts
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| Apr 2024Month disclosed | Dupixent (dupilumab) | ABBV | Topline readout | — | Positive | SEC Form 10-K |
| Apr 2024Month disclosed | Simponi® | ALVO | Topline readout | moderate to severe rheumatoid arthritis | Positive | SEC 8-K Exhibit 99.1 |
| Apr 2024Month disclosed | Aria® (golimumab) | ALVO | Topline readout | moderate to severe rheumatoid arthritis | Positive | SEC 8-K Exhibit 99.1 |
| Apr 2024Month disclosed | biosimilar | ALVO | Topline readout | — | Positive | SEC Form 10-K |
| Apr 2024Month disclosed | AMX0035 | AMLX | Topline readout | — | Missed primary endpoint | SEC Form 10-K |
| Apr 2024Month disclosed | itolizumab (EQ001) | EQ | Topline readout | — | Positive | SEC Form 10-Q |
| Apr 2024Month disclosed | — | EWTX | Topline readout | — | Positive | sec_424b |
| Apr 2024Month disclosed | SAVITRI | NBIX | Topline readout | — | Positive | SEC 8-K Exhibit 99.1 |
| Apr 2024Month disclosed | osavampator (NBI-1065845) | NBIX | Topline readout | major depressive disorder | Positive | SEC Form 10-K |
| Apr 2024Month disclosed | — | VXRT | Topline readout | — | Positive | sec_s1 |
| April 15, 2024 | sevasemten (EDG-5506) | EWTX | Topline readout | Becker | Positive | SEC Form 10-Q |
| April 23, 2024 | — | TOVX | Topline readout | — | Positive | SEC Form 10-Q |
| April 23, 2024 | zabilugene almadenorepvec (VCN-01) | TOVX | Topline readout | refractory retinoblastoma | Positive | SEC 8-K Exhibit 99.1 |
April 2024: trial starts and primary completions
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| Apr 2024Month disclosed | ZUSDURI (mitomycin) | URGN | Trial start | recurrent low-grade intermediate risk NMIBC | Completed | SEC Form 10-Q |
| Apr 2024Month disclosed | zilebesiran | ALNY | Trial start | — | Completed | SEC Form 10-Q |
| Apr 2024Month disclosed | soquelitinib (CPI-818) | CRVS | Trial start | moderate to severe atopic dermatitis | Completed | SEC Form 10-Q |
| Apr 2024Month disclosed | cardiomyopathy | LXEO | Trial start | FA cardiomyopathy | Completed | SEC Form 10-Q |
| Apr 2024Month disclosed | MNPR-101 | MNPR | Trial start | — | Completed | SEC Form 10-K |
2 more milestones are guided to a half-year or full-year window, or estimated from ClinicalTrials.gov primary completion dates, that overlaps April 2024. They are on each drug page and in the calendar API.
Questions
What PDUFA dates are in April 2024?
2 PDUFA dates fell in April 2024: ANKTIVA (April 23), IBRX (April 23). The FDA calendar also recorded 53 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
Can these dates change?
Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.